Update and summary on AREDS2

Article

The AREDS2 report has recently been published with important implications for those afflicted with early stage AMD...

The AREDS2 report has recently been published with important implications for those afflicted with early stage AMD.

In summary, AREDS2 recruited 4203 volunteers with the non-advanced form of AMD, and all subjects received broad-spectrum antioxidants (vitamin C, vitamin E, beta-carotene, zinc and copper [AREDS1 formulation or variations thereof]) with additional treatment of lutein (L) and zeaxanthin (Z) (Treatment 1), or omega-3 fatty acids (Treatment 2), or L and Z and omega-3 fatty acids (Treatment 3), or placebo.

In brief, the AREDS 2 investigators reported:

  • No statistically significant extra benefit (reduction in risk of progression to advanced AMD) for any of the Treatments 1-3 compared to placebo.
  • A statistically significant (p = 0.01) reduction of 9% in risk of progression to advanced AMD for subjects receiving L and Z when compared with subjects not receiving L and Z.
  • Participants with lowest dietary intake of L and Z showed a statistically significant (p = 0.01) reduction of 26% in risk of progression to advanced AMD for subjects receiving L and Z when compared with subjects not receiving L and Z.
  • A statistically significant (p = 0.02) reduction of 18% in risk of progression to advanced AMD for subjects receiving L and Z (plus an AREDS formulation) in the absence of beta carotene, when compared with subjects receiving an AREDS formulation with beta carotene (and not receiving L and Z).
  • A statistically significant (p = 0.01) reduction of 26% in risk of profound visual loss (i.e., neovascular AMD) for subjects receiving L and Z (plus an AREDS formulation) in the absence of beta carotene, when compared with subjects receiving an AREDS formulation with beta carotene (and not receiving L and Z).
  • Beta carotene was associated with poor absorption of L and Z, with consequentially reduced bioavailability of these carotenoids.
  • The inclusion of beta carotene in the formulation was associated with increased risk of lung cancer amongst current and past smokers.
  • There was no evidence that supplementation with omega-3 fatty acids was of benefit in any of the analyses reported in this study.
  • Supplementation with L and Z, omega-3 fatty acids or beta carotene had no statistically significant effect on visual acuity.
  • Supplementation with L and Z, omega-3 fatty acids or beta carotene had no statistically significant effect on mortality.

This summary was created by Professor John Nolan, PhD, Principal Investigator, Fulbright Scholar, Howard Fellow, ERC Fellow, Macular Pigment Research Group, Vision Research Centre, Waterford Institute of Technology, Ireland.

A more detailed summary will be published in an upcoming print issue of Ophthalmology Times Europe.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.